Scilex Holding Company

NASDAQ:SCLX

Drug Manufacturers - General

Healthcare
$6.34 -2.38%

-$0.17 today

Market cap
$53.83M
Beta
1.71
P/E (TTM)
-0.1
EPS (TTM)
-$60.90
52W Low $2.62High $21.34

Volume 0.00M

Average 0.13M

SCLX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Scilex Holding CompanyNASDAQ: SCLX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $3.63M rose 9.5% year over year, ahead of the -34.5% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +43.2% a year.

Context

  • Stock-based compensation amounted to 51.2% of revenue in FY2025, up 23.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +9.5% holds above the trailing-twelve-month pace of -34.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.63M— QoQ
Last fiscal yearDec 2025
$15.49M-1.3% YoY
LTMMar 2026
$10.16M-34.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.5%——
1 year-1.3%——
3-year CAGR+43.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
15.49M USD
Year-over-year change
-1.3%
4-year CAGR
+27.7%

Stock-Based Compensation vs competitors

How SCLX compares with its peers on the latest reported figures

  • SCLX's LTM Mar 2026 stock-based compensation of $10.16M is the 5th largest of the 9 companies compared; the peer median is $10.03M.
  • Its year-over-year change of -34.5% is the 5th highest of 8, against a peer median of -14.6%.
  • Stock-based compensation amounts to 30.0% of revenue for SCLX, versus a peer median of 59.3%.
SCLX Competitors Peer median
Stock-Based Compensation for SCLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$2.3B +49501.8%-33.1%44751.8%
ALECAlector, Inc.LTM Mar 2026$21.22M -43.4%-16.7%115.2%
SEERSeer, Inc.LTM Mar 2026$12.88M -49.1%-22.9%85.6%
AGENAgenus Inc.LTM Mar 2026$10.29M -14.6%-1.8%8.3%
SCLXScilex Holding CompanyLTM Mar 2026$10.16M -34.5%+43.2%30.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$9.77M +1.5%+47.6%—
IRDOpus Genetics, Inc.LTM Mar 2026$3.95M +20.1%+23.4%33.0%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$3.06M -44.1%-45.0%—
CTORCitius Oncology, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding SCLX) $10.03M-14.6%-16.7%59.3%

Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(88.42M)(23.36M)(114.33M)(72.81M)(358.73M)
Depreciation & Amortization3.78M3.96M4.15M4.05M4.62M
Deferred Income Tax12.76M0000
Stock-Based Compensation5.82M5.28M14.6M15.69M15.49M
Change in Working Capital13.6M45.67M65.8M64.84M113.97M
Accounts Receivables(1.14M)(6.97M)(13.36M)(6.27M)13.84M
Inventory(1.42M)1.18M(2.84M)1.46M1.8M
Accounts Payables(3.84M)2.81M19.88M7.42M13.12M
Other Working Capital20M48.65M62.12M62.23M85.21M
Other Non-Cash Items23.79M(52.8M)9.08M7.58M228.47M
Operating Cash Flow(28.66M)(21.26M)(20.71M)19.35M3.82M
Capital Expenditures0(2.07M)(330K)(600K)(133K)
Acquisitions (Net)00000
Purchases of Investments000(2.08M)0
Sales of Investments00000
Other Investing Activities00(300K)04.22M
Investing Cash Flow0(2.07M)(330K)(2.68M)4.08M
Debt Repayment(19.69M)(31.25M)728K(64.21M)(2.81M)
Common Stock Issued096K35.46M44.64M27.88M
Common Stock Repurchased00(10M)00
Dividends Paid00000
Other Financing Activities47.85M52.33M(2.6M)1.44M(30.53M)
Financing Cash Flow28.16M21.17M23.58M(18.13M)(5.46M)
Effect of Forex Changes0000(756K)
Net Change in Cash(501K)(2.15M)2.55M(1.46M)1.68M
Free Cash Flow(28.66M)(23.33M)(21.04M)18.75M3.68M

Scilex Holding Company

NASDAQ:SCLX

Intrinsic Alpha fair value

Locked

Current Price

$6.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.